Brady Kelly reported option exercise involving 92 derivative units of Seres Therapeutics, Inc. at $0.00 for $0 on Nov 15, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
See Remarks
See Remarks
Filed Nov 17, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
92Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
456Direct
Trade date
Nov 15, 2026Option exercise
Filed
Nov 17, 2026, 4:15 PM ET2-day reporting delay
Accession
0001193125-26-465539Code M · Transaction 403253
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 15, 2026Option exercise89$0.00$0Trade 403252
Nov 16, 2026Sell85$1.38−$117.30Trade 403251
Nov 15, 2026Option exercise181——Trade 403250
4 transaction rows in this filing. Joint filers share the same rows.

MCRB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MCRB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +37%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units. F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.